Primary Resistance to Immune Checkpoint Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: Focus on Nivolumab Plus Ipilimumab
Immune checkpoint inhibitors have become a standard treatment for patients with metastatic renal cell carcinoma (mRCC). The combination of nivolumab and ipilimumab has demonstrated durable responses and survival benefits; however, approximately 20%–25% of patients exhibit primary resistance and derive limited clinical...